Insider Selling: Sangamo Therapeutics Inc (SGMO) CFO Sells 5,000 Shares of Stock

Sangamo Therapeutics Inc (NASDAQ:SGMO) CFO Kathy Yi sold 5,000 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $10.00, for a total transaction of $50,000.00. Following the transaction, the chief financial officer now directly owns 30,512 shares in the company, valued at $305,120. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kathy Yi also recently made the following trade(s):

  • On Friday, March 1st, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $10.00, for a total transaction of $50,000.00.
  • On Tuesday, January 15th, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $11.04, for a total transaction of $55,200.00.

Sangamo Therapeutics stock opened at $9.74 on Wednesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.23 and a current ratio of 5.23. The firm has a market cap of $992.02 million, a price-to-earnings ratio of -13.91 and a beta of 2.83. Sangamo Therapeutics Inc has a one year low of $6.26 and a one year high of $24.45.

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. increased its position in Sangamo Therapeutics by 1.3% during the fourth quarter. BlackRock Inc. now owns 8,430,838 shares of the biopharmaceutical company’s stock worth $96,785,000 after buying an additional 108,527 shares during the last quarter. Credit Suisse AG boosted its holdings in Sangamo Therapeutics by 23.5% during the third quarter. Credit Suisse AG now owns 2,184,505 shares of the biopharmaceutical company’s stock valued at $37,027,000 after acquiring an additional 415,764 shares during the period. BB Biotech AG bought a new stake in Sangamo Therapeutics during the fourth quarter valued at about $15,498,000. Dimensional Fund Advisors LP boosted its holdings in Sangamo Therapeutics by 459.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,239,110 shares of the biopharmaceutical company’s stock valued at $14,224,000 after acquiring an additional 1,017,573 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Sangamo Therapeutics by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 1,129,365 shares of the biopharmaceutical company’s stock valued at $12,965,000 after acquiring an additional 15,750 shares during the period. 62.50% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have commented on SGMO shares. BidaskClub raised shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 9th. ValuEngine downgraded shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. Zacks Investment Research downgraded shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 18th. Finally, Wedbush set a $10.00 target price on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a research report on Sunday, March 10th. One research analyst has rated the stock with a sell rating, four have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $16.40.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Sangamo Therapeutics Inc (SGMO) CFO Sells 5,000 Shares of Stock” was posted by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.wkrb13.com/2019/03/20/insider-selling-sangamo-therapeutics-inc-sgmo-cfo-sells-5000-shares-of-stock-2.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Read More: How to calculate compound interest

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.